FAQS
A. Hemospan® is a human hemoglobin-based product that is intended to serve as an alternative to red blood cell transfusions. Hemospan® is specifically designed to the optimal molecular size, viscosity, oxygen affinity and diffusion potential to target oxygen delivery to tissues at risk of oxygen deprivation. The starting material for Hemospan® is unmodified hemoglobin derived from human red blood cells. Pharmaceutical grade polyethylene glycol (PEG) polymers are synthetic, readily available materials that are attached to the surface of hemoglobin using simple chemical reactions.
A. Hemospan® is currently undergoing clinical trials. A successful Phase II clinical trial has been completed, and a pivotal multicenter Phase III clinical program is being initiated in Europe. Upon successful completion of these trials, marketing approval will be sought.
A. The highly efficient manufacturing process of Hemospan® enables the creation of over three units of Hemospan® for every unit of blood input, providing solid economics for Hemospan®.
A. Hemospan® is unique in that it was designed to avoid the technical issues faced by first generation products. Sangart has the advantage of being able to utilize extensive research into the underlying mechanisms of cell-free oxygen transport that was not readily available when first generation products were designed. This research has enabled Sangart to understand precisely where in the circulatory system oxygen should be delivered for maximal efficiency and is counter to the conventional wisdom in the blood substitute field upon which first generation products are based.
A. No, Sangart does not have a protocol for compassionate use.